Your browser doesn't support javascript.
loading
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
Oster, Paul; Vaillant, Laurie; Riva, Erika; McMillan, Brynn; Begka, Christina; Truntzer, Caroline; Richard, Corentin; Leblond, Marine M; Messaoudene, Meriem; Machremi, Elisavet; Limagne, Emeric; Ghiringhelli, Francois; Routy, Bertrand; Verdeil, Gregory; Velin, Dominique.
Affiliation
  • Oster P; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Vaillant L; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Riva E; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • McMillan B; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Begka C; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Truntzer C; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Richard C; Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.
  • Leblond MM; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Messaoudene M; Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.
  • Machremi E; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Limagne E; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Ghiringhelli F; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Routy B; Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.
  • Verdeil G; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Velin D; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland dominique.velin@chuv.ch.
Gut ; 71(3): 457-466, 2022 03.
Article in En | MEDLINE | ID: mdl-34253574
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Helicobacter Infections / Colonic Neoplasms / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / Lung Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Animals / Female / Humans / Male Language: En Journal: Gut Year: 2022 Document type: Article Affiliation country: Suiza
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Helicobacter Infections / Colonic Neoplasms / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / Lung Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Animals / Female / Humans / Male Language: En Journal: Gut Year: 2022 Document type: Article Affiliation country: Suiza